![]() |
市場調查報告書
商品編碼
1715191
歐洲液體活體組織切片採血管市場預測(2031年)-區域分析-按產品、材料、應用和最終用戶Europe Blood Collection Tubes for Liquid Biopsy Market Forecast to 2031 - Regional Analysis - by Product, Material, Application, and End User |
2023年歐洲液體切片採集血管市場價值為309.49億美元,預計到2031年將達到1217.4227億美元;預計2023年至2031年的複合年成長率為18.7%。
液體活體組織切片相較於其他診斷檢測技術的優勢推動歐洲血液採集管用於液體活體組織切片市場
侵入性診斷程序會增加血腫、出血和組織損傷的風險,並在周圍組織中播撒腫瘤細胞。因此,越來越多的患者傾向於採用非侵入性或微創性測試來進行診斷。研究人員可以透過血液樣本的液體活體組織切片追蹤實體腫瘤中的所有遺傳和表觀遺傳學變化。由於液體活體組織切片是一種非侵入性診斷技術,因此患者的風險較小。此外,臨床醫生可以輕鬆地多次進行這些測試,因為這些過程不會對患者造成太多不適。由於使用先進的儀器,患者更喜歡微創手術,這使得臨床醫生或實驗室人員能夠以更少的疼痛、疤痕和風險進行更精細和複雜的工作。由於技術進步提高了可行性並縮短了處理時間,液體活體組織切片作為癌症患者組織活體組織切片的一種非侵入性替代方法,最近引起了人們的廣泛關注。
電腦斷層掃描 (CT)、磁振造影 (MRI) 和正子斷層掃描 (PET) 等影像技術既昂貴又耗時。此外,它們還使患者接觸外部放射線、靜脈造影劑和放射性示蹤劑等。影像學研究也無法提供關於腫瘤表現型的任何資訊,而腫瘤表現型可能會隨著治療而改變。儘管組織活體組織切片技術可以提供有關腫瘤表現型的資訊,但考慮到成本限制和患者風險,進行連續組織活體組織切片是不可行的。相反,液體活體組織切片可以以相對較低的成本提供對癌症負擔和表現型資訊的幾乎連續的評估。液體活體組織切片提供了評估各種生理或病理生理過程的非侵入性或微創性手段,從而取代組織活體組織切片或其他侵入性程序。在這種情況下,液體活體組織切片可以透過分析血液樣本中的循環腫瘤細胞或循環遊離核酸來避免內視鏡檢查、針吸活體組織切片或手術的需要。
歐洲液體切片採血管市場概況
根據2022年6月發表在《胸腔腫瘤學雜誌》的《德國肺癌》文章,癌症是德國第二大死因之一,佔所有死亡人數的25%。男性和女性的年齡標準化發生率分別為 52.1% 和 32.7%(每 10 萬人)。男性被診斷出罹患癌症的平均年齡為 70 歲,女性為 69 歲,且 52% 的患者處於 IV 期。因此,癌症發生率的不斷上升推動了德國液體活體組織切片採血管市場的成長。此外,BARMER 還涵蓋針對大腸直腸癌患者進行的 OncoBEAM RAS CRC IVD 測試。這種創新的液體活體組織切片診斷方法僅需使用單管血量即可對 RAS 突變進行全面評估。這種報銷選擇標誌著腫瘤治療現代化的一個重要里程碑,使患者能夠獲得關鍵訊息,以便及時選擇最合適的治療方法。
歐洲液體切片採血管市場收入及預測(2031年)(百萬美元)
歐洲液體切片採血管市場細分
歐洲液體切片採血管市場分為產品、材料、應用、最終用戶、國家。
根據產品,歐洲液體切片採血管市場分為 ccfDNA/cfDNA 管、cfRNA 管、CTC 管、gDNA 管、細胞內 RNA 管等。 2023 年,ccfDNA/cfDNA 管部門佔據歐洲液體活體組織切片採血管市場的最大佔有率。
從材質來看,歐洲液體切片採血管市場分為塑膠和玻璃。 2023 年,塑膠製品佔據了歐洲液體活體組織切片採血管市場的較大佔有率。
根據應用,歐洲液體切片採血管市場分為體外診斷(IVD)和研究。 2023 年,體外診斷 (IVD) 領域佔據了歐洲液體活體組織切片採血管市場的較大佔有率。
就最終用戶而言,歐洲液體活體組織切片採血管市場分為基因診斷實驗室、研發中心、傳統診斷中心和其他。 2023 年,基因診斷實驗室部門佔據歐洲液體活體組織切片採血管市場的最大佔有率。
根據國家/地區,歐洲液體活體組織切片採血管市場分為英國、德國、法國、義大利、西班牙和歐洲其他地區。 2023 年,德國佔據歐洲液體活體組織切片採血管市場的最大佔有率。
Biocept公司;精確科學公司; F.霍夫曼-羅氏有限公司; Greiner Bio-One International GmbH; MagBio Genomics 公司; Norgen Biotek 公司; QIAGEN NV;斯特雷克公司;和 Zymo Research Corporation 是歐洲液體活體組織切片採血管市場領先的公司之一。
The Europe blood collection tubes for liquid biopsy market was valued at US$ 30,949.00 million in 2023 and is expected to reach US$ 1,21,742.27 million by 2031; it is estimated to register a CAGR of 18.7% from 2023 to 2031.
Advantages of Liquid Biopsy Over Other Diagnostic Testing Techniques Drive Europe Blood Collection Tubes for Liquid Biopsy Market
Invasive diagnostic procedures increase the risk of hematoma, hemorrhage, and tissue damage, seeding tumor cells in surrounding tissues. As a result, there is a growing preference for noninvasive or minimally invasive tests among patients for diagnostic purposes. Researchers can trace all genetic and epigenetic changes in solid tumors through the liquid biopsy of blood samples. Patients are at lesser risk with liquid biopsies, since it is a noninvasive technique of diagnosis. Moreover, clinicians can readily conduct these tests multiple times, as the procedures don't subject patients to much discomfort. Patients prefer minimally invasive procedures due to the use of advanced instruments, which allow clinicians or laboratory personnel to perform more delicate and complex work with less pain, scarring, and risk. Liquid biopsy has recently gathered considerable interest as a noninvasive alternative to tissue biopsy in cancer patients, owing to technological advancements contributing to improved feasibility and reduced processing times.
Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scan, among other imaging techniques, are expensive and time-consuming. Moreover, they expose patients to external radiation, intravenous contrast, and radioactive tracers, among others. Imaging studies also fail to provide any information about the phenotype of the tumor, which can change with the treatment given. Although tissue biopsy techniques can offer information on tumor phenotype information, it is not feasible to perform serial tissue biopsies, considering cost limitations and risks to patients. Liquid biopsy, on the contrary, could provide a virtually continuous assessment of cancer burden and phenotype information at a relatively low cost. Liquid biopsy offers noninvasive or minimally invasive means of assessing various physiological or pathophysiological processes, thereby replacing tissue biopsy or other invasive procedures. Liquid biopsy, in this case, could circumvent the need for endoscopy, needle biopsy, or surgery by analyzing a blood sample for circulating tumor cells or circulating free nucleic acids.
Europe Blood Collection Tubes for Liquid Biopsy Market Overview
According to the "Lung Cancer in Germany" article, published in the Journal of Thoracic Oncology in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. With an age-standardized incidence rate of 52.1% and 32.7% (per 100,000) in men and women, respectively. The average age at which individuals are diagnosed with cancer is 70 years in men and 69 years in women, and 52% of the total patients are at stage IV. The increasing prevalence of cancer thus fuels the growth of the blood collection tubes for liquid biopsy market in Germany. Moreover, BARMER covers the OncoBEAM RAS CRC IVD Test performed in colorectal cancer patients. This innovative liquid biopsy diagnostic method delivers a comprehensive evaluation of RAS mutations using blood volume as low as a single tube. This reimbursement option marks an important milestone in the modernization of oncology care, granting patients access to critical information for the timely selection of the most appropriate therapy.
Europe Blood Collection Tubes for Liquid Biopsy Market Revenue and Forecast to 2031 (US$ Million)
Europe Blood Collection Tubes for Liquid Biopsy Market Segmentation
The Europe blood collection tubes for liquid biopsy market is categorized into product, material, application, end user, country.
By product, the Europe blood collection tubes for liquid biopsy market is segmented into ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, intracellular RNA Tubes, and others. The ccfDNA/cfDNA Tubes segment held the largest share of the Europe blood collection tubes for liquid biopsy market share in 2023.
In terms of material, the Europe blood collection tubes for liquid biopsy market is segmented into plastic and glass. The plastic segment held a larger share of the Europe blood collection tubes for liquid biopsy market share in 2023.
By application, the Europe blood collection tubes for liquid biopsy market is bifurcated into in-vitro diagnostics (IVD) and research. The in-vitro diagnostics (IVD) segment held a larger share of the Europe blood collection tubes for liquid biopsy market share in 2023.
In terms of end user, the Europe blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, research and development centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held the largest share of the Europe blood collection tubes for liquid biopsy market share in 2023.
Based on country, the Europe blood collection tubes for liquid biopsy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany segment held the largest share of Europe blood collection tubes for liquid biopsy market in 2023.
Biocept Inc; Exact Sciences Corp; F. Hoffmann-La Roche Ltd; Greiner Bio-One International GmbH; MagBio Genomics, Inc; Norgen Biotek Corp; QIAGEN NV; Streck Inc; and Zymo Research Corporation are some of the leading companies operating in the Europe blood collection tubes for liquid biopsy market.